Scientists analyzed blood samples for “molecular markers indicating advanced colorectal cell changes” and then compared the results with colonoscopy findings. The test showed a sensitivity of 81.1% in detecting existing colon cancer and a specificity of 90.4% in ruling out the disease.
According to lead researcher Dr. Aasma Shaukat from NYU Grossman School of Medicine, additional convenient and safe colorectal cancer screening methods are required. The experimental blood test represents a promising new option for enhancing screening rates.
Colorectal cancer ranks as the fourth most common cancer and the second deadliest in the U.S. The study’s findings suggest that blood-based screening could offer a convenient and effective screening choice for average-risk individuals.
Dr. Pamela Kunz from Yale School of Medicine described the blood test as a valuable addition to existing colorectal cancer screening tools. Dr. Pashtoon Kasi, a specialist at City of Hope Orange County, highlighted the transformative potential of liquid biopsies in cancer care.
While blood tests provide an early cancer detection method, colonoscopies remain essential for preventing colon cancer by removing precancerous growths. Early detection significantly improves outcomes in colon cancer cases.
The hope is that the blood test will encourage more individuals to undergo screenings and ultimately contribute to better outcomes in colorectal cancer treatment.
“It conjures up unpleasant thoughts of bowel prep, a liquid diet and embarrassment, so it is not surprising that blood screening tests offer greater appeal,” he said, referring to the blood-based test as a “potential game-changer” in enhancing screening rates. “Colorectal cancer is on a particularly sharp incline – so sharp that by the year 2030, it will become the leading cause of cancer death for young adults in the United States,” cautioned an oncologist. With more individuals being diagnosed with colon cancer before the age of 50, expanded screening options are crucial.
“It will be imperative to expand research in this area and to have diagnostic testing available for a younger demographic,” Kasi warned. Colorectal cancer ranks as the fourth most prevalent cancer in the U.S. and as the second deadliest type, according to the Colorectal Cancer Alliance. Doctors emphasized that while blood tests are valuable, they should not replace colonoscopies, which remain the “gold standard” of colon cancer screening.
Moving forward, researchers will continue to assess the long-term effects of the colorectal blood test. “As blood-based tests gain approval from regulatory bodies and Medicare and other payors, they will become accessible for clinical use,” lead study author Shaukat informed Fox News Digital. Blood-based tests are suitable for men and women aged 45 to 85 who are at average risk for colon cancer and are due for screening, the doctor highlighted.
A recent study linked cooking oil to colon cancer, attributed to inflammation. “If you have a family history or a medical condition that increases your risk for colon cancer, this test may not be a suitable option,” he explained. “Moreover, if the test results are positive, a colonoscopy is necessary to examine for colon polyps or cancer.”
For more health-related articles, please visit www.foxnews.com/health. The researcher advises patients to consult their healthcare providers about options for colorectal cancer screening, which may include stool tests, blood tests, and colonoscopies, and choose the most suitable one for them. The study mentioned did not receive any funding, as stated in the release.
